secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001493152-22-017439
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic discloses JV IPO target and OT-101 COVID mortality data at BIO2022
----------------------------------------------------------------------------

- JVCo IPO on track for 2023 with anticipated minimum valuation of $200M, range $1-5B.
- OT-101 combined with immunotherapies including Keytruda (Merck), Tecentriq (Genentech); in various stages.
- OT-101 treatment of high-risk COVID patients reduced mortality from 100% to 50% (p=0.003).
- Company presentation at BIO International Convention available on website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222017439/0001493152-22-017439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222017439/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-017439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer